As for triple-wild melanoma, analysis with larger gene panels is worthwhile, as it has a higher probability to find targets for tumor-agnostic targeted therapies in this tumor type, such as RET, NTRK (neurotrophic tyrosine receptor kinase), ALK (anaplastic lymphoma kinase) or even IDH1 mutations [13]. This evidence concerns the gene IDH1 and melanoma.